-
2023-507777-18-00
4
2019-03-19
Advanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL
-
2022-502747-35-00
5
2019-02-18
Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ova
-
2023-508424-34-00
5
2019-02-11
Moderate to Severe Plaque Type Psoriasis
-
2024-512158-12-00
5
2018-12-14
Bladder Cancer
Muscle-Invasive Bladder Cancer
-
2024-511553-22-00
5
2018-10-05
Moderately to Severely Active Crohn's Disease
-
2023-508472-11-00
5
2018-06-13
Patients with early breast cancer
-
2024-517928-19-00
4
2018-04-17
Male and female patients with histologically confirmed diagnosis of re
-
2023-510200-42-00
5
2017-12-06
primary sclerosing cholangitis (PSC)
-
2022-501251-81-00
5
2017-06-08
Renal cell carcinoma
-
2024-512934-14-00
5
2016-11-07
advanced or metastatic adenocarcinoma of the stomach or gastroesophage
-
2024-518022-33-00
5
2016-07-15
Advanced Stage of Hodgkin Lymphoma
-
2023-509137-39-00
5
2015-11-06
Stage IB (T ≥ 4 cm), II and IIIA NSCLC
-
2023-504761-23-00
5
2014-11-19
Advanced or metastatic renal cell carcinoma
-
2022-501474-19-00
7
Non-Small Cell Lung Cancer
-
2022-502040-13-00
4
High-risk Myelodysplastic neoplasia
-
2022-502233-25-00
5
Schizophrenia
-
2023-505735-13-01
9
Atopic dermatitis
-
2024-512804-20-00
5
Metastatic Colorectal Cancer
-
2024-515487-31-00
6
HIV-infected
-
2024-515630-33-00
5
Symptomatic leg vein thrombosis
-
2024-516073-74-00
6
Unresectable or metastatic melanoma with a BRAF V600 mutation (inopera
-
2025-520468-16-00
4
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable
-
2025-522054-40-00
4
Previously treated advanced melanoma
-
2025-522750-39-00
5
Erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD)